Immunomic Therapeutics, a Hershey, PA-based clinical stage vaccine platform technology company, raised $3m in funding.
Among others, backers included Mid Atlantic Bio Angels (MABA), which injected $400k via individual investors and family members.
The company intends to use the capital to fund more in-depth clinical trials leading to a product acquisition.
Led by Dr. Bill Hearl, CEO, Immunomic Therapeutics is developing innovative vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology, which has the potential to increase the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery.
The company has lab facilities in Rockville, MD.